An association between NETs and COVID-19 severity could encourage new treatment approaches, such as DNases [25], recombinant human DNase-I [48], IL-8 receptor antagonists [30], certain monoclonal antibodies, PAD4 or nicotinamide adenine dinucleotide phosphate (NADPH) inhibitors [49], Fostamatinib [50], Resolvin T-series [51], and current and novel histone inhibitors [36]. This evidence concerns the gene PADI4 and COVID-19.